Lonza signs LightPath discovery agreement with LegoChem
To provide pre-clinical material of novel therapeutic compound
Lonza has agreed to supply South Korean biotechnology firm LegoChem Biosciences with a monoclonal antibody that will be used for preclinical studies.
Under the agreement, Lonza will produce the material using LightPath discovery services at its applied protein services facility in Cambridge, UK.
Lonza’s LightPath discovery service provides non-GMP product in 6 to 10 weeks, to support customers in the discovery testing phase.
Since its launch last year, Lonza says it has seen increased demand for this technology, which aims to reduce timelines to IND filing.
